These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 2360803

  • 1. The short-duration response to apomorphine: implications for the mechanism of dopaminergic effects in parkinsonism.
    Gancher ST, Woodward WR, Gliessman P, Boucher B, Nutt JG.
    Ann Neurol; 1990 Jun; 27(6):660-5. PubMed ID: 2360803
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Apomorphine test: evaluation of dopaminergic response in patients with Parkinson disease].
    Miranda M, Saéz D.
    Rev Med Chil; 1995 Mar; 123(3):326-9. PubMed ID: 8525172
    [Abstract] [Full Text] [Related]

  • 6. Apomorphine test for dopaminergic responsiveness: a dose assessment study.
    Bonuccelli U, Piccini P, Del Dotto P, Rossi G, Corsini GU, Muratorio A.
    Mov Disord; 1993 Apr; 8(2):158-64. PubMed ID: 8474482
    [Abstract] [Full Text] [Related]

  • 7. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Blanchet PJ, Konitsiotis S, Chase TN.
    J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Brain dopamine receptor stimulation and the relief of Parkinsonism: relationship between bromocriptine and levodopa.
    Rinne UK, Marttila R.
    Ann Neurol; 1978 Sep; 4(3):263-7. PubMed ID: 718139
    [Abstract] [Full Text] [Related]

  • 10. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
    Sonsalla PK, Manzino L, Heikkila RE.
    J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Dopamine receptor stimulating agonists in the treatment of Parkinson's disease.
    Agid Y, Barroche G, Bonnet AM, Javoy-Agid F, Kato G, Lhermitte F, Pollak P, Signoret JL.
    Biomedicine; 1979 Jun; 30(2):67-71. PubMed ID: 383169
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Apomorphine in patients with Parkinson's disease.
    Muguet D, Broussolle E, Chazot G.
    Biomed Pharmacother; 1995 Jun; 49(4):197-209. PubMed ID: 7669939
    [Abstract] [Full Text] [Related]

  • 18. Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease.
    Vaamonde J, Luquin MR, Obeso JA.
    Mov Disord; 1990 Jun; 5(3):260-2. PubMed ID: 2388647
    [Abstract] [Full Text] [Related]

  • 19. 123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism.
    Schwarz J, Tatsch K, Arnold G, Gasser T, Trenkwalder C, Kirsch CM, Oertel WH.
    Neurology; 1992 Mar; 42(3 Pt 1):556-61. PubMed ID: 1549216
    [Abstract] [Full Text] [Related]

  • 20. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease.
    Tison F, Wiart L, Guatterie M, Fouillet N, Lozano V, Henry P, Barat M.
    Mov Disord; 1996 Nov; 11(6):729-32. PubMed ID: 8914103
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.